Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL
Open Access
- 29 November 2019
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 9 (12) , 1-11
Abstract
B-cell precursor (BCP) ALL carry a variety of classical V(D)J rearrangements as well as genomic fusions and translocations. Here, we assessed the value of genomic capture high-throughput sequencing (gc-HTS) in BCP ALL (n = 183) for the identification and implementation of targets for minimal residual disease (MRD) testing. For TRδ, a total of 300 clonal rearrangements were detected in 158 of 183 samples (86%). Beside clonal Vδ2-Dδ3, Dδ2-Dδ3, and Vδ2-Jα we identified a novel group of recurrent Dδ-Jα rearrangements, comprising Dδ2 or Dδ3 segments fused predominantly to Jα29. For IGH-JH, 329 clonal rearrangements were identified in 172 of 183 samples (94%) including novel types of V(D)J joining. Oligoclonality was found in ~1/3 (n = 57/183) of ALL samples. Genomic breakpoints were identified in 71 BCP-ALL. A distinct MRD high-risk subgroup of IGH-V(D)J-germline ALL revealed frequent deletions of IKZF1 (n = 7/11) and the presence of genomic fusions (n = 10/11). Quantitative measurement using genomic fusion breakpoints achieved equivalent results compared to conventional V(D)J-based MRD testing and could be advantageous upon persistence of a leukemic clone. Taken together, selective gc-HTS expands the spectrum of suitable MRD targets and allows for the identification of genomic fusions relevant to risk and treatment stratification in childhood ALL.Keywords
This publication has 52 references indexed in Scilit:
- Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemiaBlood, 2012
- Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemiaBlood, 2012
- Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyThe Lancet Oncology, 2012
- Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemiaBritish Journal of Haematology, 2011
- Molecular characterization of a novel chromosomal translocation t(12;14)(q23;q11.2) in T‐lymphoblastic lymphoma between the T‐cell receptor delta‐deleting elements (TRDREC and TRAJ61) and the hypothetical gene C12orf42European Journal of Haematology, 2010
- Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocolLeukemia, 2009
- B‐cell precursor t(8;14)(q11;q32)‐positive acute lymphoblastic leukemia in children is strongly associated with Down syndrome or with a concomitant Philadelphia chromosomeEuropean Journal of Haematology, 2008
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataLeukemia, 2007
- Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALLLeukemia, 2005
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998